CureVac Announces Changes of CDO – Myriam Mendila to succeed Klaus Edvardsen

• Myriam Mendila appointed as Chief Development Officer starting from February 1, 2023
• Klaus Edvardsen returning to Denmark after holding numerous leadership positions in the U.S. and Europe
• Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development Officer

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”) today announced that Chief Development Officer Klaus Edvardsen will leave the company on June 30, 2022. He plans to return home to Denmark for a new professional opportunity. CureVac is pleased to welcome Myriam Mendila to this key role. Myriam’s appointment will take effect on February 1, 2023. Until then, Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development Officer.

CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

• CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backbone
• The partnership combines CureVac’s mRNA technology with myNEO’s platform for the discovery and selection of tumor antigens predicted to elicit strong immune responses
• Together with myNEO, CureVac aims to identify specific antigens for the development of novel mRNA cancer vaccines

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and myNEO N.V., a Belgium-based immunotherapy company, today announced that they have entered into a research and option agreement. Under the agreement, both companies aim to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies. To achieve this goal, myNEO will leverage its biological datasets and its integrated machine learning and bioinformatics platform to identify and validate specific antigen targets predicted to elicit a strong immune response.

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update

• Executing on broad vaccine development program, with new clinical studies in COVID-19 and influenza together with GSK to validate advanced second-generation mRNA backbone
  – Initiated Phase 1 dose-escalation study in COVID-19 with CV2CoV, validating mRNA backbone for further variant adaptation
  – Fully recruited Phase 1 dose-escalation study in influenza with differentiated multivalent vaccine candidate, CVSQIV, confirmed good tolerability profile across all doses
• Bivalent approach for combined Beta/Delta-COVID-19 vaccine candidate shows promising preclinical data, with high neutralizing capacity against each variant, as well as against Omicron
• Increasing momentum in oncology pipeline by focusing on new avenues for T cell activation as well as access to novel classes of antigens and antigen discovery platforms
• Launched fully owned subsidiary, CureVac RNA Printer GmbH, to accelerate development of The RNA Printer® with dedicated infrastructure and experienced management
• Executed contract with German government for pandemic preparedness together with GSK, providing access to developed vaccines and CureVac’s manufacturing capacity
• Cash position of €811.5 million as of December 31, 2021. EU confirms no obligation to repay upfront payment for Advanced Purchase Agreement for first-generation candidate, CVnCoV

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the fourth quarter and full-year 2021 and provided a business update.

CureVac and GSK’s Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study

• Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study
• Demonstrated neutralizing capacity against the Omicron variant in vaccinated animals
• Technology adaptation for bivalent approach for COVID-19 vaccines potentially allows for broader protection against emerging variants

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced preclinical data demonstrating immune responses and protective efficacy of a bivalent second-generation COVID-19 vaccine candidate jointly developed with GSK, combining two mRNAs encoding for the Beta and the Delta variant.

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

• Phase 1 dose-escalation study started at clinical sites in the U.S.
• Milestone demonstrates CureVac’s and GSK’s continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK. The clinical trial is expected to provide valuable data to further evaluate the performance of CureVac’s second-generation mRNA backbone, which has the potential to be applied broadly in future vaccines against COVID-19 variants and other pathogens.